Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy ...

CAR T-cell therapy modifies a patient's immune cells to target cancer, offering potential cures for blood cancers like lymphoma and myeloma. Up to 40% of lymphoma patients may achieve remission after ...

Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

A new generation of CAR T cell therapy is bringing hope in the fight against cancer, targeting not only blood cancers but also solid tumors such as ovarian and breast cancer. Fraunhofer researchers ...

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...